Rapport Therapeutics, Inc.

RAPP Nasdaq SEC CIK 2012593
Follow Rapport Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $0
Net income −$40.2M −49.4% vs same quarter last year
EPS, diluted −$0.84 −18.3% vs same quarter last year
Operating cash flow −$41.6M −138.4% vs same quarter last year
Revenue by quarter
$0
$0
$0
$20M
$0
$0
Q1 25 Q2 25 Q3 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income4 fiscal years
−$150M−$100M−$50M$0FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$111.5M
FY24−$78.3M
FY23−$34.8M
FY22-
Free cash flowOperating cash flow minus capital expenditure
−$100M−$75M−$50M−$25M$0FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$88.1M
FY24−$67.2M
FY23−$28.8M
FY22-